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Improvement after two sessions of
electroconvulsive therapy predicts ﬁnal
remission in in-patients with major
depression
Birkenhager TK, Roos J, Kamperman AM. Improvement after two
sessions of electroconvulsive therapy predicts ﬁnal remission in in-
patients with major depression.
Objective: To investigate whether early improvement, measured after
two electroconvulsive therapy (ECT) sessions, is a good predictor of
eventual remission in severely depressed in-patients receiving ECT.
Method: A prospective cohort study was performed that included 89
major depressive disorder in-patients treated with bilateral ECT.
Sensitivity, speciﬁcity, and predictive values were computed for various
deﬁnitions of early improvement (15%, 20%, 25%, and 30% reduction
on the Montgomery Asberg depression rating scale (MADRS) score)
after 1 week (i.e. two sessions) of ECT regarding prediction of
remission (ﬁnal MADRS score ≤ 9).
Results: A 15% reduction in MADRS score appeared to be the best
deﬁnition of early improvement, with modest sensitivity (51%) and
relatively good speciﬁcity (79%). Kaplan–Meier analysis showed a
more than 2-week shorter time to remission in patients with early
improvement compared with patients lacking early improvement.
Conclusion: Early improvement during an ECT course may be assessed
after two ECT sessions. Such improvement, deﬁned as a 15% reduction
in the MADRS score, is a moderately sensitive predictor for eventual
remission in an in-patient population with severe major depression.
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Signiﬁcant outcomes
• Early improvement after two ECT sessions is a predictor for ﬁnal remission
• Attainment of remission occurs more than 2 weeks earlier in patients with early remission
• Lack of early improvement may contribute to treatment decision-making in patients receiving ECT.
Limitations
• The sample size of the study is relatively small.
• The homogeneity of the sample may limit generalizability of the results to patients with less severe
major depression.
• The exclusion of patients refusing further ECT sessions may have overestimated the eﬃcacy of ECT.
Introduction
Electroconvulsive therapy (ECT) is an eﬀective
acute treatment for patients with severe major
depressive disorder in need of rapid response,
either with or without medication resistance. In
severe major depression, ECT has the highest rates
of response and remission of any form of antide-
pressant treatment, with 70–90% of those treated
showing response (1). Some even report clinical
improvement after the ﬁrst ECT session (2).
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Following extensive research on the prediction
of outcome of ECT in major depression, several
clinical predictors for higher eﬃcacy of ECT have
been determined. These include the absence of
medication resistance (3, 4), psychotic symptoms
(4, 5), advanced age (5), and shorter duration of
the index episode (4). With regard to polarity of
mood disorder, this variable appears to have no
inﬂuence on the eﬃcacy of ECT. Whether the pres-
ence of melancholic features is a predictor for a
higher eﬃcacy of ECT remains uncertain (5).
Early improvement as a predictor of the ﬁnal
outcome in the treatment of depression has been
investigated. Some studies showed that the largest
improvement on ECT may take place during the
ﬁrst weeks of the ECT course (6, 7). Most studies
investigating the predictive value of early improve-
ment employed the Hamilton Depression Rating
Scale (HAM-D) (8). Several studies found that the
best predictor of eventual response or remission
was the reduction in HAM-D score after 3-6 ECT
sessions (9, 10). More recently, Lin et al. (2019),
investigating 104 patients, showed that ﬁnal
response and remission could be predicted by an
early improvement of 30% after six ECT sessions,
but that early improvement after three sessions
had less discriminative value. Another recent study
found that a 30% improvement after six ECT ses-
sions appeared to be a good predictor of remission
in depressed in-patients (11). The assessment of
early improvement may be clinically relevant, since
this may guide decision-making during the ECT
course with regard to electrode placement, dosing,
and treatment schedule. However, six ECT ses-
sions might be midway, rather than early, in the
ECT course. Therefore, it may not be the optimal
time point to measure early improvement.
Aim of the study
The primary aim of the present study was to assess
whether early improvement, measured after two
electroconvulsive therapy (ECT) sessions, is a good
predictor of eventual remission in severely
depressed in-patients receiving ECT. The cutoﬀ
will be chosen based on the area under the curve,
which represents a balance between sensitivity and
speciﬁcity. The secondary aim was to analyze dif-
ferences in time to remission between patients with
and without early improvement.
Methods
The PROspective Study on Patients receiving ECT
(PROSPECT) is a prospective study of depressed
patients treated with ECT at the Department of
Psychiatry of the Erasmus Medical Center from
January 2006 to date (12). The end date for the
present sample was December 2015. Patients are
included in the PROSPECT cohort if they meet
the DSM-IV criteria (13) for major depressive dis-
order (MDD) with or without psychotic features
and have a score of ≥17 on the 17-item Hamilton
Rating Scale for Depression (HAM-D) (8). Diag-
noses are based on clinical observations during a
routine drug-free observation period. A diagnosis
of mood-congruent psychotic depression is made
only when the patient shows deﬁnite mood-con-
gruent delusions and/or hallucinations. A subset of
adult PROSPECT patients (aged ≥ 18 years) was
selected for the current analyses. Excluded were all
patients with alcohol or drug dependence, a diag-
nosis of schizophrenia, schizoaﬀective disorder,
bipolar disorder, psychotic disorder not otherwise
speciﬁed, obsessive-compulsive disorder, dementia,
and other neurological disorders. To avoid elec-
trode placement acting as a confounding factor,
only patients treated with bitemporal ECT were
selected. Although both a recent randomized trial
(14) and a recent meta-analysis found no diﬀerence
in eﬃcacy between high-dose unilateral and bitem-
poral ECT in MDD (15), there might be diﬀer-
ences in terms of speed of response. To avoid bias,
of those patients receiving more than one ECT
course during this period, only the ﬁrst treatment
course was included in the analysis.
The study was conducted in accordance with the
latest version of the Declaration of Helsinki, and
informed consent of the participants was obtained
after the nature of the procedures had been fully
explained. Since all data were obtained as part of
standard psychiatric care, medical ethical review
was not deemed necessary.
ECT protocol
Patients were withdrawn from all psychotropic
medication at least 5 days prior to the ﬁrst ECT
treatment, and the majority of patients were main-
tained medication-free during the course of ECT.
In case of severe agitation, incidental use of
haloperidol was allowed, whereas the use of benzo-
diazepines during ECT was not allowed. All
patients were treated with bilateral ECT, adminis-
tered twice weekly with a brief-pulse constant cur-
rent apparatus (Thymatron IV, Somatics, IL,
USA). We used a pulse width of 0.5 ms and a pulse
amplitude of 900 mA. Seizure threshold, deﬁned
as the stimulus dosage that elicited a seizure of at
least 25 s according to the cuﬀ method, was deter-
mined during the ﬁrst session with empirical stimu-
lus titration. If the starting stimulus dose failed to
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elicit a seizure of at least 25 s, stimulus charge was
increased according to the titration schedule and
the patient was restimulated after 30 s. For the sec-
ond treatment, the stimulus dosage was set at 1.5
times the seizure threshold. During the course of
ECT, stimulus dosage settings were adjusted
upward to maintain a seizure duration of at least
25 s as measured with the cuﬀ method. Anesthesia
was achieved after premedication with 0.2 mg gly-
copyrrolate, with intravenous administration of
etomidate (0.2 mg/kg), alfentanil (7–10 lg/kg),
and succinylcholine (0.5–1.0 mg/kg). During the
procedure, patients were ventilated by mask until
the resumption of spontaneous respiration. Physio-
logical monitoring included pulse oximetry, non-
invasive blood pressure measurement, electrocar-
diogram, and electroencephalogram. The number
of ECT treatments was determined by clinical
observation; a minimum of 10 bilateral treatments
was required before evaluation as a non-responder.
ECT was continued until patients were either
asymptomatic (i.e. a MADRS score ≤ 9) or had
not shown any further improvement as measured
by the MADRS over the course of three consecu-
tive treatments (i.e. a MADRS score ≥ MADRS
score 2 weeks previously).
Outcome measurement
The Montgomery Asberg Depression Rating Scale
(MADRS) was used to evaluate the severity of
MDD and was routinely performed 1–3 days prior
to the ECT and 1–3 days after treatment termina-
tion to evaluate the eﬃcacy of ECT. Since the
MADRS (16) is more sensitive to detect small
changes over time (17), it was performed weekly,
during ECT treatment to evaluate the time to
remission. The MADRS was performed by two
independent residents, who were not involved in
decisions about the duration of the ECT course.
To ensure comparable ratings, inter-rater training
sessions took place once a month, aiming at a dif-
ference of ≤2 points in total MADRS score. The
primary outcome criterion for eﬃcacy is the pro-
portion of patients in remission (dichotomous) as
measured by the MADRS. The secondary out-
come criterion is time to remission as measured by
the MADRS. Remission was deﬁned as a MADRS
score of ≤9 at the end of the ECT course. Also, a
baseline MADRS score was taken before the start
of the treatment. The MADRS scores were used
for the present study; percentage improvement
after 1 week of treatment was calculated with the
MADRS score in week one (i.e. after receiving two
ECT sessions) relative to the MADRS score at
baseline, resulting in two study groups (early
improvement vs. no early improvement).
Statistical analysis
Statistical analyses were performed with SPSS, ver-
sion 24.0. Alpha was set at 0.05. Diﬀerences with
regard to sociodemographic, clinical, and outcome
variables between subgroups of patients were
tested with t-tests or an ANOVA test for continuous
variables, and Pearson’s chi-square and Fisher’s
exact test (FET) for categorical variables. To
determine the best deﬁnition of early improvement
after 1 week of treatment, four deﬁnitions of early
improvement were used (15%, 20%, 25%, and
30% reduction in baseline MADRS score) and
analyzed in relation to the following measures: sen-
sitivity (proportion of remitters, who achieved
early improvement), speciﬁcity (proportion of non-
remitters who did not achieve early improvement),
positive predictive value (PPV, proportion of
patients with early improvement, who remitted),
and negative predictive value (NPV, proportion of
patients without early improvement who did not
remit). Furthermore, a receiver operating (ROC)
analysis was performed. The area under the ROC
curve (AUC) was used to assess the accuracy of
the analysis to distinguish remitters from non-
remitters. Diﬀerences in the rate of remission
between the two subgroups were determined using
the chi-square test. Finally, diﬀerences in the time
to remission between the subgroups were analyzed
using the Kaplan–Meier method (18, 19).
Data imputation was done for patients with
missing values: for nine patients, the mean
MADRS score was calculated for single or multi-
ple missing values, provided that the baseline
MADRS was known. In one patient, last observa-
tion carried backwards was done because the base-
line MADRS score was the only missing value and
no other missing data during the subsequent treat-
ment course; we decided to adopt a last observa-
tion carried backward imputation method instead
of excluding this case.
Results
Patient characteristics
Between 2006 and 2015, 190 patients received
ECT; of these, 85 were excluded because they did
not meet the inclusion criteria or they fulﬁlled one
or more exclusion criteria. Six patients refused fur-
ther ECT sessions or were transferred to another
hospital, and 10 patients were excluded due to a
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missing baseline MADRS score or because no
weekly MADRS score was available (e.g. in
patients with very severe depression with catatonic
features and/or mutism).
Finally, 89 patients were included in the present
study (Fig. 1); 65% were female, and mean age
was 63.9 (SD 12.4, range 33–96) years. Of these
patients, 54 (61%) had depression with psychotic
features, 29% had an episode duration >1 year,
and the mean baseline MADRS score was 38.3
(SD 8.2). Table 1 presents the clinical characteris-
tics of the total sample, and for the two subgroups
with and without remission. No signiﬁcant diﬀer-
ences between the two subgroups were found for
age, sex, previous pharmacotherapy failure, epi-
sode duration, the presence of psychotic features,
and the baseline MADRS score. Response was
attained by 77 (87%) patients, while 65 (73%)
attained full remission.
Analysis of four definitions of early improvement
The predictive value of early improvement was
analyzed as a predictor of eventual remission. As
mentioned, remission was deﬁned as a ﬁnal
MADRS score ≤9. To investigate the predictability
of early improvement to predict eventual remis-
sion, we calculated sensitivity, speciﬁcity, PPV,
NPV, and AUC. For early improvement, several
deﬁnitions were used, that is, a ≥15%, 20%, 25%,
or 30% reduction on the MADRS score at week 1,
after two ECT sessions (Table 2). The results show
that early improvement is a modestly sensitive pre-
dictor for eventual remission. Using a higher cutoﬀ
level tends to decrease the sensitivity; for example
the ≥15% cutoﬀ level for early improvement shows
a higher sensitivity compared with the higher cut-
oﬀ levels of early improvement. To identify a pre-
dictor with both acceptable speciﬁcity and
sensitivity, ROC curves were constructed that
Total number of patients
receiving ECT treatment
between 2006-2015
(n = 190) Excluded (n = 85)
Patients with multiple
ECT courses 31
Bipolar disorder 13
Schizo-affective disorder 3
Schizophrenia 17
Other psychotic disorder 4
Obsessive compulsive
disorder 1
Personality disorder 2
Unilateral ECT 13
Age < 18 years 1
Included (n = 105)
Dropouts (n = 16)
Baseline or weekly MADRS score
not obtainable 10
Stopped due to medical advice, or
transferred 6
Analyzed (n = 89)
Fig. 1. Flowchart of inclusion of study
sample.
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compared a ≥15%, 20%, 25%, and 30% reduction
on the MADRS score at week 1. The AUC for the
predictor 15% improvement at week 1 to predict
eventual remission was 0.65, indicating modest
predictability. The AUCs for the other deﬁnitions
of early improvement were only slightly inferior.
Figure 2 shows the relatively poor sensitivity of
the predictor: of the 51 patients not achieving early
improvement after 1 week of ECT, 32 (63%) were
remitters at the end of the ECT course. The fairly
good speciﬁcity of the predictor is also shown: of
the 38 patients achieving early improvement after
1 week of ECT, only 5 (13%) were non-remitters
at the end of the ECT course.
Relation between early improvement and time to remission
A 15% reduction in MADRS score was used as
deﬁnition of early improvement, in order to assess
its inﬂuence on the time of the ECT course
required to attain full remission. The Kaplan–
Meier curve (Fig. 2) shows that remission was
achieved more than 2 weeks earlier in patients who
attained early improvement (i.e. 15% reduction in
the MADRS score) compared with those who did
not; this diﬀerence was signiﬁcant (Breslow test
Χ2 = 12.67, P = 0.01).
Moreover, a sensitivity analysis was performed,
calculating time to remission with remission
deﬁned as an MADRS score ≤ 6. Patients meeting
the criterion for early improvement attained remis-
sion after 7.72 (95% CI 6.52–8.91) weeks vs. 10.81
(9.84–11.77) weeks in patients without early
improvement (Breslow test v2 = 16.64, P < 0.001).
Discussion
This study shows that early improvement within
1 week (i.e. two sessions) of bilateral ECT is a
moderately sensitive predictor for time to remis-
sion in an in-patient population with severe major
depression. However, 87% of the patients that
achieved early improvement became remitters,
whereas as much as 63% of the patients without
early improvement attained eventual remission.
Therefore, lack of early improvement is not useful
to predict who will not beneﬁt from ECT. Regard-
ing the secondary aim of the present study, remis-
sion was attained more than two weeks earlier in
patients with early improvement. A faster resolu-
tion of depressive symptoms is associated with a
better prognosis (20). Therefore, lack of early
improvement appears to have clinical relevance.
As suggested previously (11), changes in treatment
schedule, dosing, or augmentation with an antide-
pressant may be considered for patients without
early improvement. Regarding the best deﬁnition
of early improvement, it should be noted that the
AUCs of the four deﬁnitions were similar. The
15% improvement on the MADRS score appears
to be the most appropriate deﬁnition, since its
modest sensitivity (51%) only decreases when
using larger percentages of reduction on the
MADRS score as a deﬁnition of early improve-
ment. Remarkably, patients without early
improvement still showed a favorable treatment
eﬀect. At the end of the ECT course, 32/51 patients
(63%) met the criteria for eventual remission.
These results show that continuing the ECT course
is a sensible strategy, even for patients failing to
achieve early improvement.
Comparison with previous studies
Two recent studies investigated the same topic; in
these studies, early improvement was measured
after 2 weeks of ECT with a three session/week
schedule (10, 11), that is, after six ECT sessions.
Table 1. Clinical characteristics of the study sample (n = 89)
No
remission
(n = 24)
Remission
(n = 65)
Total
(n = 89) Test
Female, n (%) 12 (50) 46 (71) 58 (65) Χ2 = 3.33,
P = 0.07
Age in years,
mean  SD
66.2  15.5 63  11.1 63.9  12.4 t = 0.92,
P = 0.37
Pharmacotherapy
failure, n (%)
20 (83) 47 (72) 67 (75) Χ2 = 1.15,
P = 0.29
Episode
duration > 1 year,
n (%)
8 (33) 18 (28) 26 (29) Χ2 = 0.27,
P = 0.61
Psychotic features,
n (%)
12 (50) 42 (65) 54 (61) Χ2 = 1.57,
P = 0.21
Previous ECT
treatment
6 (25) 13 (20) 19 (21) Χ2 = 0.26,
P = 0.77
Baseline MADRS
score, mean  SD
38.7  5.5 38.1  9.0 38.3  8.2 T = 0.84,
P = 0.40
Baseline HAM-D
score, mean  SD
28.2  6.2 29.7  6.9 28.8  6.5 t = 1.07,
P = 0.29
Number of ECT
sessions,
mean  SD
18.0  4.6 13.5  4.4 14.7  4.8 t = 4.24,
P < 0.001
Table 2. Estimates of early improvement (after 1 week of ECT) for prediction of
remission
% Early improvement Sensitivity Specificity PPV NPV AUC
15 0.51 0.79 0.87 0.37 0.65
20 0.42 0.79 0.84 0.33 0.60
25 0.37 0.91 0.92 0.35 0.64
30 0.32 0.96 0.95 0.34 0.64
PPV, positive predictive value; NPV, negative predictive value; AUC, area under the
curve.
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The authors found a 30% reduction in the HAM-
D score to be the best deﬁnition of early improve-
ment. Both studies included severely depressed in-
patients with high baseline HAM-D scores, similar
to the patient sample in the present study. In par-
ticular, in the study by Martinez-Amoros et al.,
the patient sample appears to be comparable to
that of our study, with ≥50% of patients suﬀering
from psychotic depression, and an average age of
66 years. However, because of the diﬀerence in
the number of ECT sessions after which early
improvement was measured, it is diﬃcult to make
a meaningful comparison between that study and
the present study. Nevertheless, predicting remis-
sion after six ECT sessions may be relatively easy,
since for many patients this is midway, rather than
early, in their ECT course. The possibility of pre-
dicting eventual remission particularly early in the
ECT course is more surprising, although it has
been described previously (2, 7). The previous
studies that investigated early improvement as a
predictor of response to antidepressant drugs (21–
23) usually deﬁned early improvement as a reduc-
tion of ≥20% in the HAM-D score after 2 weeks
of treatment with antidepressants. However, since
ECT is used for patients who tend to be more
severely depressed, and often in need of a rapid
antidepressant eﬀect, measuring early improve-
ment after 2 weeks of ECT may not be the opti-
mal choice. A greater eﬃcacy and faster onset of
action of ECT (1, 9) should emerge earlier than
after 2 weeks of treatment. When early improve-
ment as predictor is compared with a prediction
model for the eﬃcacy of ECT, the Maudsley Stag-
ing Method (MSM) (24), three diﬀerences between
both methods are apparent: the MSM is assessed
prior to the ECT course, while early improvement
is measured during the ECT course. Moreover,
the MSM is a score on a scale, whereas early
improvement is a dichotomous predictor. Finally,
van Diermen et al. (24) used the MSM to assess
the probability of remission with ECT, while early
improvement also was used to assess time to
remission. In clinical practice, the MSM may be
used to support the decision to perform ECT,
whereas early improvement may be helpful to
assess whether adaptations in the ECT method are
necessary.
Strengths and limitations
Strengths of this study include (i) making the diag-
nosis of major depression during a drug-free obser-
vation period resulting in a homogeneous sample
of patients with severe depression and (ii) its
prospective design. Furthermore, refraining from
the use of benzodiazepines during the ECT course
is regarded as a strength, because these agents have
a negative eﬀect on the eﬃcacy of right unilateral
(RUL) ECT (25); this may also apply to bilateral
(BL) ECT. A limitation of the study is the homo-
geneity of our patient sample, implying that the
results may not be generalizable to patients with
less severe major depression. Unfortunately, we
have no follow-up data on our sample, which is a
limitation. Moreover, the relatively small sample
size (n = 89) is another limitation. Since only
severely depressed in-patients receive ECT at our
center, the high response (87%) and remission
(73%) rate may not be feasible for patients with
less severe major depression. Finally, since BL
ECT was exclusively used, our ﬁndings may not be
applicable to patients receiving RUL or bifrontal
ECT.
Fig. 2. Kaplan–Meier curve: time to
remission in both subgroups. Mean
time to remission in early improvers:
6.49 weeks, 95% CI 5.61–7.36; In
patients without early improvement:
8.82 weeks, 95% CI 7.94–9.69. Breslow
test: Χ2 = 12.67, P = 0.01.
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To conclude, early improvement during an ECT
course may be assessed after two ECT sessions.
Such an improvement is a moderately sensitive
predictor for eventual remission in an in-patient
population with severe major depression. Final
remission was attained over 2 weeks earlier in
patients with early improvement, which may be
considered a clinically relevant diﬀerence. How-
ever, although it takes them more time, eventually
the majority of patients without early improve-
ment also became remitters. Therefore, the lack of
early improvement should not necessarily be a rea-
son to stop ECT prematurely. This could lead to
considering changes in treatment schedule, dosing,
or augmentation with an antidepressant.
Data availability
The data concerning the present study are available upon
request.
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